Anthera Pharmaceuticals to Present at Rodman & Renshaw’s 18th Annual Global Investment Conference
September 06 2017 - 8:30AM
Anthera Pharmaceuticals, Inc. (Nasdaq:ANTH), a
biopharmaceutical company focused on developing and commercializing
products to treat serious and life-threatening diseases, including
exocrine pancreatic insufficiency and IgA nephropathy, announced
today that Craig Thompson, President & Chief Executive
Officer, will present a corporate update at Rodman & Renshaw’s
18th Annual Global Investment Conference.
The presentation will be at 10:25 AM ET, September
12th, at the Lotte New York Palace Hotel in New York.
The audio portion of the presentation will be accessible through
the company’s Investors page at
www.anthera.com/investors following the presentation.
About Anthera Pharmaceuticals, Inc.
Anthera Pharmaceuticals is a biopharmaceutical company
focused on developing and commercializing products to treat serious
and life-threatening diseases, including exocrine pancreatic
insufficiency and IgA nephropathy. Additional information on
Anthera can be found at www.anthera.com.
Safe Harbor Statement
Any statements contained in this press release that refer to
future events or other non-historical matters, including statements
that are preceded by, followed by, or that include such words as
"estimate," "intend," "anticipate," "believe," "plan," "goal,"
"expect," "project," or similar statements, are forward-looking
statements made pursuant to the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. These
forward-looking statements are based on Anthera's expectations as
of the date of this press release and are subject to certain risks
and uncertainties that could cause actual results to differ
materially as set forth in Anthera's public filings with
the SEC, including Anthera's Quarterly Report on Form 10-Q for
the quarter ended June 30, 2017. Anthera disclaims any
intent or obligation to update any forward-looking statements,
whether because of new information, future events or otherwise,
except as required by applicable law.
Contact Information
CONTACT: Investor Relations of Anthera Pharmaceuticals, Inc.
ir@anthera.com
For Media Inquiries:
Srikant Ramaswami
rbb Communications
srikant.ramaswami@rbbcommunications.com
718-710-1350
www.twitter.com/antherapharma
https://www.facebook.com/antherapharma/
https://www.linkedin.com/company/anthera-pharmaceuticals
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Mar 2024 to Apr 2024
Anthera Pharmaceuticals (CE) (USOTC:ANTH)
Historical Stock Chart
From Apr 2023 to Apr 2024